K36 Ther­a­peu­tics rais­es $70M in Se­ries B to fund mul­ti­ple myelo­ma re­search

K36 Ther­a­peu­tics raised $70 mil­lion to help fund an on­go­ing clin­i­cal tri­al for its lead and on­ly can­di­date, an oral mul­ti­ple myelo­ma treat­ment.

The Cam­bridge …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER